These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 15228371)

  • 21. The cost effectiveness and budget impact of natalizumab for formulary inclusion.
    Bakhshai J; Bleu-Lainé R; Jung M; Lim J; Reyes C; Sun L; Rochester C; Shaya FT
    J Med Econ; 2010 Mar; 13(1):63-9. PubMed ID: 20028199
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical remission with biologic therapies in severe asthma: a matter of definition.
    Beasley R; Noble J; Weatherall M
    Eur Respir J; 2023 Dec; 62(6):. PubMed ID: 38097202
    [No Abstract]   [Full Text] [Related]  

  • 23. Biological therapies need definitive randomized controlled clinical trials.
    Califf RM; Marks PW
    Sci Transl Med; 2023 Jan; 15(680):eadg2970. PubMed ID: 36696486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biologic Organization and the Cancer Problem.
    Burr HS
    Yale J Biol Med; 1940 Jan; 12(3):277-82. PubMed ID: 21433882
    [No Abstract]   [Full Text] [Related]  

  • 25. New challenges to medicare beneficiary access to mAbs.
    Cohen J; Wilson A
    MAbs; 2009; 1(1):56-66. PubMed ID: 20046575
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care?
    Balkrishnan R; Bhosle MJ; Fleischer AB; Feldman SR
    J Dermatolog Treat; 2010 May; 21(3):178-84. PubMed ID: 19821787
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticipating the future: how the emergence of innovative biologic agents impacts benefit design, utilization, and provider relations.
    Lipsy RJ; Fuller MG; Roski J; Mansukani S
    J Manag Care Pharm; 2004 May; 10(3 Suppl):S4-9; quiz S19. PubMed ID: 15228370
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost per responder associated with biologic therapies for Crohn's disease, psoriasis, and rheumatoid arthritis.
    Liu Y; Wu EQ; Bensimon AG; Fan CP; Bao Y; Ganguli A; Yang M; Cifaldi M; Mulani P
    Adv Ther; 2012 Jul; 29(7):620-34. PubMed ID: 22843208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Injectable biologic case studies.
    Lipsy RJ
    J Manag Care Pharm; 2004 May; 10(3 Suppl):S10-6; quiz S20. PubMed ID: 15228371
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Considerations for assessing the cost of biologic agents in the treatment of psoriasis.
    Rich SJ
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S38-41. PubMed ID: 15253689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical update on alefacept: consideration for use in patients with psoriasis.
    Gade JN
    J Manag Care Pharm; 2004 Jun; 10(3 Suppl B):S33-7. PubMed ID: 15253688
    [TBL] [Abstract][Full Text] [Related]  

  • 33.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 34.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.